Scarica l'app Stockscreener
6.64
0.91%
0.06
Dopo l'orario di chiusura:
6.66
0.02
+0.30%
Precedente Chiudi:
$6.58
Aprire:
$6.52
Volume 24 ore:
59,554
Relative Volume:
0.18
Capitalizzazione di mercato:
$21.17M
Reddito:
$1.22M
Utile/perdita netta:
$-22.43M
Rapporto P/E:
-5.742
EPS:
-1.1564
Flusso di cassa netto:
$-18.78M
1 W Prestazione:
+0.91%
1M Prestazione:
+801.81%
6M Prestazione:
+645.23%
1 anno Prestazione:
+730.00%
Intervallo 1D:
$6.50
$6.7999
Intervallo di 1 settimana:
$6.50
$6.90
Portata 52W:
$0.475
$7.299
Longeveron Inc Stock (LGVN) Company Profile
Nome
Longeveron Inc
Settore
Industria
Telefono
305-302-7158
Indirizzo
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
6.64 | 20.98M | 1.22M | -22.43M | -18.78M | -1.1564 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
Longeveron Inc Borsa (LGVN) Ultime notizie
192,308 Longeveron (NASDAQ: LGVN) shares sit with one passive fund - Stock Titan
LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design - Stocktwits
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
Longeveron Stock Price Forecast. Should You Buy LGVN? - StockInvest.us
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming DeadlineLGVN - TMX Newsfile
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
A biotech presentation is set for New York on Sept. 14 - Stock Titan
Longeveron | 4: Statement of changes in beneficial ownership of securities - Moomoo
Longeveron (LGVN) Gains 2.68% as Shares Hold Above Key Support at $6.55Breakout Confirmation - vinanet.vn
Longeveron To Carry Out 1-for-10 Reverse Stock Split On August 27th, 2026 - Moomoo
Longeveron Announces 1-for-10 Reverse Stock Split to Regain Nasdaq Compliance - Intellectia AI
Dick's Sporting Goods, Intuit And 3 Stocks To Watch Heading Into Tuesday - Sahm
Longeveron Announces 1-for-10 Reverse Stock Split - The National Law Review
Longeveron Announces 1-For-10 Reverse Stock Split - TradingView
Longeveron Inc. Earnings Call: Trials, Cash and Risk - TipRanks
Longeveron (NASDAQ: LGVN) insider logs new stock trades - Stock Titan
Longeveron (LGVN) grants director 36,000 stock units - Stock Titan
Longeveron (NASDAQ: LGVN) insider reports new stock dealings - Stock Titan
Longeveron (NASDAQ: LGVN) insider reports stock trades - Stock Titan
Longeveron (LGVN) Q2 2026 Earnings Call Transcript - AOL.ca
Longeveron (LGVN) Earnings Reading: Profit Per Share Falls Below Its Benchmark at the Close; After Results: The Stock Gains 4.46% in the Current UpdateEarnings Sentiment Score - dars.gov.et
Longeveron appoints Nirav Jhaveri as chief financial officer - Investing.com Nigeria
Longeveron Appoints Nirav Jhaveri as CFO Ahead of September Trial Data - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Longeveron CFO Marie Washburn to switch roles, Nirav Jhaveri to succeed - TipRanks
Longeveron Appoints New Chief Financial Officer Jhaveri - TipRanks
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer - The Manila Times
Longeveron Appoints Nirav Jhaveri As CFO - marketscreener.com
Longeveron appoints Nirav Jhaveri as chief financial officer By Investing.com - Investing.com India
Longeveron Inc. Appoints Nirav Jhaveri as Chief Financial Officer - Quiver Quantitative
Marie Washburn Net Worth (2026) - GuruFocus
Longeveron reports Q2 EPS (19c) vs. (33c) last year - TipRanks
$Longeveron (LGVN.US)$ - Moomoo
Longeveron Inc. (LGVN) investors disclose 9% beneficial stake through warrant holdings - Stock Titan
Longeveron LLC earnings missed by $0.01, revenue fell short of estimates - Investing.com Nigeria
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update - BioSpace
Longeveron Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Longeveron Q2 EPS $(0.19) Misses Estimate, Sales Fall 9% - scanx.trade
LGVN: Q2 2026 net loss rose to $6.1M as HLHS trial data and XPRIZE finalist status drive near-term focus - TradingView
Earnings call transcript: Longeveron misses Q2 2026 estimates as cash runs tight - Investing.com
Longeveron Inc. (LGVN) Q2 FY2026 earnings call transcript - Yahoo Finance
Longeveron Reports $6.1 Million Q2 Net Loss Ahead Of ELPIS II Data - Quiver Quantitative
Longeveron Q2 net loss widens on higher legal, clinical trial costs - TradingView
LGVN: Q2 2026 net loss rose 22% as clinical and legal expenses increased ahead of key trial results - TradingView
BRIEF-Longeveron Q2 EPS USD -0.19 - TradingView
Longeveron Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Longeveron (LGVN) Rises 7.92% to $0.75, Approaches Key Resistance at $0.79Retracement Entry - vinanet.vn
Earnings To Watch: Longeveron Inc (LGVN) Q2 2026 -- GF Value Sees 58% Downside - Yahoo Finance
Longeveron Selected as XPRIZE Healthspan Milestone 2 Awardee for Laromestrocel Clinical Trial Results - Quiver Quantitative
Longeveron Named a Finalist Team and Will Receive a - GlobeNewswire
Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition - The Manila Times
Longeveron Inc Azioni (LGVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):